The Institute for Clinical and Economic Review (ICER) announced the release of its final report on Spinraza and Zolgensma for treatment of spinal muscular atrophy, and in it recommended a major price reduction for Spinraza.
No recommendation was made on Zolgensma’s price since its treatment price was not yet known.
Spinraza currently costs $750,000 for the first year of treatment and $375,000 for each consecutive year. ICER in its report recommends a price range of $72,000-$130,000 for the first year and $36,000-$65,000 for each consecutive year.
“Both Spinraza and Zolgensma dramatically improve the lives of children with SMA and that of their families,” ICER CMO David Rind said in a statement. “However, the current price of Spinraza far exceeds common thresholds for cost-effectiveness.”
To read the full press release on ICER’s website, click here.
